Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: Juracy B. S. Júnior Clear advanced filters
  • Primary CoronaVac vaccination followed by a BNT162b2 booster dose confers protection against some SARS-CoV-2 variants but its effectiveness against Omicron is unknown. Here, the authors show that this combination confers a high level of protection against severe outcomes for up to 120 days, with evidence of waning for those aged 80 or older.

    • Thiago Cerqueira-Silva
    • Vinicius de Araujo Oliveira
    • Manoel Barral-Netto
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-6
  • There is limited evidence of the effectiveness of the CoronaVac vaccine for children against the Omicron SARS-CoV-2 variant. Here, the authors use data from Brazil for children aged 6–11 years and estimate effectiveness of 40% against infection and 59% against severe disease at least two weeks after the second dose.

    • Pilar T. V. Florentino
    • Flávia J. O. Alves
    • Enny S. Paixão
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-5
  • A test-negative case–control analysis of data from Brazil shows that vaccine effectiveness against SARS-CoV-2 infection and severe COVID-19 outcomes declines after two doses of CoronaVac but increases after a booster dose of the BNT162b2 vaccine.

    • Thiago Cerqueira-Silva
    • Srinivasa Vittal Katikireddi
    • Viviane S. Boaventura
    ResearchOpen Access
    Nature Medicine
    Volume: 28, P: 838-843